Literature DB >> 31857555

Recurrent Guillain-Barré Syndrome - Case Series.

Ivana Basta1, Ivo Bozovic1, Ivana Berisavac1, Olivera Stojiljkovic-Tamas1, Sonja Lukic Rajic2, Aleksandra Dominovic-Kovacevic3, Aleksandar Stojanov4, Gordana Djordjevic4, Dejana Jovanovic1, Stojan Peric1.   

Abstract

Recurrent Guillain-Barré syndrome (RGBS) episodes appear in up to 6% of Guillain-Barré syndrome (GBS) patients. The purpose of this study was to identify patients with previous episodes of GBS and to assess their clinical features in a large cohort of adult GBS patients. GBS patients hospitalized at tertiary centers in three Balkan countries were included in the study (n = 404). We identified 13 (3.2%) patients with recurrent GBS (RGBS). The male to female ratio was 3: 1. All RGBS patients had two episodes of the disease. The most common GBS subtype in both episodes of the disease was acute inflammatory demyelinating polyradiculoneuropathy (AIDP) (77%, first episode; 85%, second episode). Around 23% of patients presented with a different variant during the second GBS attack. Disability seems to be equally severe at both episodes (P > 0.05). Recurrent GBS was registered in 3% of our GBS patients. The majority of them were younger males. Different GBS subtypes were found to recur.

Entities:  

Keywords:  Disability; Guillain-Barré syndrome; recurrent episode; variants

Mesh:

Year:  2019        PMID: 31857555     DOI: 10.4103/0028-3886.273649

Source DB:  PubMed          Journal:  Neurol India        ISSN: 0028-3886            Impact factor:   2.117


  4 in total

1.  Clinical efficacy of high-dose intravenous gammaglobulin in acute Guillain-Barre syndrome and effect on serum concentration of inflammatory factors.

Authors:  Lifeng Lv; Haijuan Xu; Haining Zhang; Qinde Qi
Journal:  Am J Transl Res       Date:  2022-09-15       Impact factor: 3.940

2.  Guillain-Barré syndrome after SARS-CoV-2 vaccination in a patient with previous vaccine-associated Guillain-Barré syndrome.

Authors:  Ling Ling; Sean M Bagshaw; Pierre-Marc Villeneuve
Journal:  CMAJ       Date:  2021-11-22       Impact factor: 8.262

3.  Guillain-Barré Syndrome After Ad26.COV2.S Vaccination.

Authors:  Hein Linn Thant; Richard Morgan; Mario M Paese; Trevor Persaud; Jose Diaz; Lina Hurtado
Journal:  Am J Case Rep       Date:  2022-02-14

4. 

Authors:  Ling Ling; Sean M Bagshaw; Pierre-Marc Villeneuve
Journal:  CMAJ       Date:  2022-01-24       Impact factor: 8.262

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.